Repurposing of medications for pulmonary arterial hypertension
© The Author(s) 2020..
This manuscript on drug repurposing incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in pulmonary hypertension. Drug repurposing, use of a drug in a disease for which it was not originally developed, in pulmonary arterial hypertension has been a remarkable success story, as highlighted by positive large phase 3 clinical trials using epoprostenol, bosentan, iloprost, and sildenafil. Despite the availability of multiple therapies for pulmonary arterial hypertension, mortality rates have modestly changed. Moreover, pulmonary arterial hypertension patients are highly symptomatic and frequently end up on parental therapy and lung transplant waiting lists. Therefore, an unmet need for new treatments exists and drug repurposing may be an important avenue to address this problem.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Pulmonary circulation - 10(2020), 4 vom: 14. Okt., Seite 2045894020941494 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Toshner, Mark [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Drug repurposing |
|---|
| Anmerkungen: |
Date Revised 30.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1177/2045894020941494 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM318480662 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM318480662 | ||
| 003 | DE-627 | ||
| 005 | 20240330234255.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1177/2045894020941494 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1356.xml |
| 035 | |a (DE-627)NLM318480662 | ||
| 035 | |a (NLM)33282182 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Toshner, Mark |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Repurposing of medications for pulmonary arterial hypertension |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 30.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. | ||
| 520 | |a This manuscript on drug repurposing incorporates the broad experience of members of the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative as an open debate platform for academia, the pharmaceutical industry and regulatory experts surrounding the future design of clinical trials in pulmonary hypertension. Drug repurposing, use of a drug in a disease for which it was not originally developed, in pulmonary arterial hypertension has been a remarkable success story, as highlighted by positive large phase 3 clinical trials using epoprostenol, bosentan, iloprost, and sildenafil. Despite the availability of multiple therapies for pulmonary arterial hypertension, mortality rates have modestly changed. Moreover, pulmonary arterial hypertension patients are highly symptomatic and frequently end up on parental therapy and lung transplant waiting lists. Therefore, an unmet need for new treatments exists and drug repurposing may be an important avenue to address this problem | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a drug repurposing | |
| 650 | 4 | |a preclinical studies | |
| 650 | 4 | |a pulmonary hypertension | |
| 700 | 1 | |a Spiekerkoetter, Edda |e verfasserin |4 aut | |
| 700 | 1 | |a Bogaard, Harm |e verfasserin |4 aut | |
| 700 | 1 | |a Hansmann, Georg |e verfasserin |4 aut | |
| 700 | 1 | |a Nikkho, Sylvia |e verfasserin |4 aut | |
| 700 | 1 | |a Prins, Kurt W |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pulmonary circulation |d 2011 |g 10(2020), 4 vom: 14. Okt., Seite 2045894020941494 |w (DE-627)NLM207988838 |x 2045-8932 |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2020 |g number:4 |g day:14 |g month:10 |g pages:2045894020941494 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1177/2045894020941494 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2020 |e 4 |b 14 |c 10 |h 2045894020941494 | ||